Efficacy of fesoterodine over 24 hours in subjects with overactive bladder
Autor: | Martin C. Michel, Zhonghong Guan, Jon D. Morrow, David R. Staskin, Joseph T. Wang, Victor W. Nitti |
---|---|
Přispěvatelé: | Other Research, Pharmacology and pharmacotherapeutics |
Rok vydání: | 2010 |
Předmět: |
Adult
Male medicine.medical_specialty Evening Urology Urinary incontinence Muscarinic Antagonists Placebo Drug Administration Schedule Post-hoc analysis Fesoterodine medicine Humans Benzhydryl Compounds Least-Squares Analysis Trial registration Aged Randomized Controlled Trials as Topic Morning Aged 80 and over Dose-Response Relationship Drug Urinary Bladder Overactive business.industry General Medicine Middle Aged medicine.disease Overactive bladder Female medicine.symptom business medicine.drug |
Zdroj: | Current medical research and opinion, 26(4), 813-818. Taylor and Francis Ltd. |
ISSN: | 1473-4877 0300-7995 |
DOI: | 10.1185/03007990903585707 |
Popis: | Fesoterodine is an antimuscarinic agent indicated for the treatment of overactive bladder (OAB) symptoms. The objective of this study was to evaluate the efficacy of fesoterodine versus placebo over selected intervals during a 24-hour period in subjects with OAB. In a post hoc analysis, data were analyzed from two randomized, double-blind, placebo-controlled 12-week phase III trials in which subjects with a history of OAB symptoms for 6 months were treated with morning doses of fesoterodine 4 mg, fesoterodine 8 mg, or placebo. These trials are registered at ClinicalTrials.gov (NCT00220363 and NCT00138723). Changes were evaluated in number of micturitions, urgency episodes, urgency urinary incontinence (UUI) episodes, and mean voided volume (MVV) divided into three 8-hour intervals: 08:00-15:59 (daytime), 16:00-23:59 (evening), and 00:00-07:59 (nighttime). Comparisons with placebo were made using analysis of covariance (for least squares mean changes) and Wilcoxon rank sum test (for median percent changes); differences were considered significant at p |
Databáze: | OpenAIRE |
Externí odkaz: |